Marx, Ph.D., president, and chief operating officer. “We are very encouraged by the results of this level-1 human clinical study in an extremely challenging environment,” said Jeffrey G. “This is now our fourth prospective clinical study in which i-FACTOR Bone Graft has demonstrated a clear clinical benefit and builds upon our previously reported fusion in various spine applications.” “This study is a valuable addition to our clinical evidence base,” said Glen Kashuba, chief executive officer of Cerapedics. Longer term follow-up to evaluate the maintenance of clinical outcomes is in process. Patient reported outcomes at baseline and follow-up were similar between the two groups. Results showed the fusion rate was significantly higher in the i-FACTOR bone graft group (50 percent) compared to the allograft group (20 percent) at one year (p <0.001). Participants suffered from degenerative spondylolisthesis and underwent decompression and non-instrumented posterolateral fusion surgery, randomized to either i-FACTOR bone graft or fresh frozen allograft bone, both mixed with local bone graft. Michael Kjær Jacobsen, at the Center for Spine Surgery and Research in Southern Denmark, led the double-blind, prospective, randomized study in more than 100 patients (60 years or older). “i-FACTOR shows an increased fusion rate versus allograft.”ĭr. Michael Kjær Jacobsen, principal investigator. “In Scandinavia, surgeons often consider performing non-instrumented fusion when there is instability in elderly patients, but allograft bone has notoriously low fusion rates in this population,” said Dr. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate compared to allograft plus local bone. Engineering a solution to provide appropriate levels of cable protection is a critical element for any installation project and essential in providing all our customers with peace of mind for the long-term resilience of their critical subsea assets.WESTMINSTER, Colorado, - Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. ![]() Simon Hibberd, managing director of SBSS added, “We’re really pleased to have executed this project successfully for our customer. ![]() “The operational team is definitely well trained and experienced in their scope of responsibility and we look forward to working with SBSS in the future.” We are extremely happy with the support and commitment offered by the SBSS team,” said Abu Bakar Sutan Taharudin, CEO of Ifactors. ![]() “ It’s been a pleasure having the opportunity to work with SBSS. The second 61.9 km cable was installed between Besut to Perhentian Kecil, in Malaysia with 13.4 km buried to a depth of 3 meters. The first cable was installed between Rompin to Pulau Tioman in Malaysia, with the entire length buried for enhanced cable protection, with a length of 5.5 km buried by the Hi-plough to a depth of 3 meters. ![]() The installation and burial of 72.4 km of fibre optic cable was completed by the cable ship the Bold Maverick, utilizing both the Hi-plough and remotely operated vehicle (ROV) Sea Lion. Submarine Systems (SBSS) has completed the Stingray fibre optic cable installation project for Ifactors in Malaysia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |